GMED GLOBUS MEDICAL INC

XNYS 76.05 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

GMED $76.05 —
Key stats
$76.05
52-Week Range
$70.39 – $101.40
YTD
-12.89%
IV Rank (30D)
22.4
Straddle Price
$6.33
P/C Vol Ratio
0.68
Market Cap
$9.4B
Open
$72.12
Day Range
$71.91 – $76.27
Volume
2,021,330
Prev Close
$71.05
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.90%
Beta vs SPY0.97
Cost of Equity (CAPM)9.77% (VRP-adj)
WACC9.80%
Volatility Risk Premium+0.3pp (IV − HV30)
Effective Tax Rate18.9%
Rev. Growth (YoY, DCF input)+2.7%
DCF Horizon12 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$0.8B
Return on Equity (TTM)11.2%
Book / Price48.9% — banking bias active (P/B is primary)
Gross Margin (TTM)68.5%
FCF Margin (TTM)24.0%
Debt / Equity0.00
Quality Score4/6 — high quality (12y DCF)
Market-Implied Growth+0.3% (reverse-DCF on current price)
SMA 50$77.20 (Market Anchor value)
SMA 20 / Bollinger Mid$79.22
Bollinger Width / SMA2016.7% (drives anchor stability)
Net Debt$-0.5B
Market Cap$10B
Peers used for multiples: ABT, ALGN, MDT (filtered from 8 ETF-co-members; sector bias active)
60-Day Conviction
47%
20-Day Fair Value
≈ by Dec 8, 2026
$76.48
α +0.5% rank 14%
conviction
36%
40-Day Fair Value
≈ by Jan 6, 2027
$77.72
α +2.1% rank 19%
conviction
66%
60-Day Fair Value
≈ by Feb 4, 2027
$77.43
α +1.7% rank 30%
conviction
47%
MethodImplied PriceWeightDetail
DCF $81.77 23%
DDM (Gordon) n/a 0%
Peer P/E $108.76 7% median 27.2× · 3 peers
Peer EV/EBITDA $117.54 7% median 16.0× · 3 peers
Peer P/B $92.68 7% median 2.7× · 3 peers
Peer P/S $83.91 7% median 3.6× · 3 peers
Market Anchor (SMA50) $77.20 30% stability 66% (BB-width)
Options Expected (B-L 30d) $67.86 20% 18 strikes · skew -0.48
As of 2026-11-09 · updated
About
Industry (SIC)
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS (3841) · industry map
Exchange
XNYS
Market Cap
$9.4B
Employees
6,000
List Date
2012-08-03
CIK
0001237831
Last Earnings
Nov 5 after close · −12.8% vs ±11.5% expected
Next Earnings
~Feb 23, 2027 (estimated)
Headquarters
Audubon, PA
Homepage
https://www.globusmedical.com

Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'21'22'23'24'25'26Avg
Jan-2.60%-9.75%3.20%-0.70%13.31%3.87%1.22%
Feb1.58%5.17%-24.31%2.88%-13.25%6.42%-3.58%
Mar-1.61%4.06%-2.14%-1.49%-7.63%-8.14%-2.83%
Apr16.04%-13.06%2.16%-6.29%-2.21%2.78%-0.10%
May1.26%0.77%-6.80%33.08%-16.78%-10.36%0.19%
Jun7.52%-12.66%8.23%2.68%0.10%-0.97%0.82%
Jul5.83%1.68%3.68%5.95%-12.57%3.41%1.33%
Aug-1.29%0.63%-8.27%3.71%16.39%-0.11%1.84%
Sep-7.32%1.69%-8.45%-0.89%-4.39%-6.93%-4.38%
Oct-2.32%10.11%-7.82%4.46%2.95%4.89%2.04%
Nov-19.70%10.42%-2.33%14.33%48.76%-4.30%*7.86%
Dec14.44%-1.63%15.82%-1.42%-2.76%--4.89%
Total6.88%-5.95%-28.48%65.23%7.17%-10.60%5.71%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $79.21
SMA 50: $77.06
SMA 200: $83.06
Current: $76.12
EMA 12: $78.86
EMA 26: $78.57
MACD: 0.2842 | Signal: -0.5967
BULLISH
ADX (14): 23.04
WEAK TREND
+DI: 22.37
−DI: 27.24

Momentum Oscillators

RSI (14): 46.66
NEUTRAL
Stoch %K: 27.82
Stoch %D: 47.70
Williams %R: -67.66

Volume & Volatility

BB Upper: $85.84
BB Lower: $72.59
NEUTRAL
OBV: -21,361,408
Vol SMA 20: 1,874,170
Vol ROC: 95.31%
ATR: $3.76
True Range: $5.22
HV 20: 78.0%
HV 30: 65.0%
HV 60: 49.2%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-11-08T00:00:00 – 2026-11-06T00:00:00
AI Analysis
Written before GMED’s Nov 5 earnings report, so it doesn’t reflect the results.

Here is the LLM Stock Analysis Report:

Executive Summary

  • Overall Assessment: NEUTRAL with confidence level 5/10
  • Key Drivers:
    • Positive news sentiment around medical device growth and Globus Medical's acquisition of Nevro Corp.
    • Bullish technical signals from RSI and MACD indicators
  • Primary Risks:
    • High volatility and beta (1.12) indicating a high-risk profile
    • Options market pricing in $6.22 move by expiration, which may lead to increased price action
  • Recent News Sentiment Impact: Positive news headlines have contributed to the stock's recent upswing.

Technical Analysis

  • Trend Direction:
    • Short-term: Bullish (price above SMA 20 and EMA 12)
    • Medium-term: Neutral (price within trading range of SMAs 50 and 200)
    • Long-term: Bearish (price below SMA 200, but with upward momentum from MACD)
  • Support/Resistance Levels:
    • Upper Bollinger Band: $96.07
    • Middle Band: $84.06
    • Lower Band: $72.05
  • Momentum Signals:
    • RSI: Neutral (50.22), indicating no clear buy or sell signal
    • MACD: Bearish (signal line below -2.20), suggesting potential for further declines

News & Sentiment Analysis

  • Recent Headlines Summary: Positive news headlines around medical device growth and Globus Medical's acquisition of Nevro Corp.
  • Sentiment Assessment: Aggregate sentiment is positive, with 5 out of 6 recent headlines having a positive tone.
  • Catalyst Identification:
    • Upcoming events: No significant events announced
    • Regulatory changes: None mentioned in recent news
    • Market Narrative: The medical device industry's growth and Globus Medical's acquisition of Nevro Corp. have contributed to the stock's recent upswing.

Risk & Volatility Assessment

  • Beta Interpretation: High risk profile (beta 1.12) indicating a high-risk profile
  • Volatility Regime: Current volatility is above average, with IV rank at 86.2% and expected move of $6.22 by expiration.
  • Options Market Signals:
    • IV rank: 86.2% (High)
    • Put/Call Volume Ratio: 0.66 (Bullish sentiment)
    • Put/Call OI Ratio: 0.73

Market Context & Positioning

  • Sector Performance: Medical device sector has been trending upward
  • Institutional Activity: No significant institutional activity observed in recent trading sessions.
  • Correlation Analysis: The stock's price movements are positively correlated with the medical device sector (R-squared interpretation).
  • Relative Valuation: The stock is positioned within its trading range.

Key Levels & Action Items

  • Critical Price Levels:
    • Support at $84.06 (SMA 20)
    • Resistance at $96.07 (Upper Bollinger Band)
  • Breakout/Breakdown Levels:
    • Breakout above $96.07 could lead to further gains
    • Breakdown below $72.05 could lead to deeper declines
  • Time-Sensitive Catalysts: No significant events or announcements scheduled.
  • Risk Management: Consider stop-loss levels at $76.81 and $94.57, and position sizing considerations based on options market signals.

Please note that this analysis is neutral in its overall assessment, reflecting the mixed technical and news sentiment. The report highlights both bullish and bearish cases, as well as potential risks and opportunities for the stock.

Generated
Earnings History
19 of 24 under expected move
Avg Expected Move
8.05%
Avg Actual Move
7.30%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2021-02-17 After-Close 6.44% 4.83% 0.75x Within
2021-05-04 After-Close 6.48% 5.36% 0.83x Within
2021-08-04 After-Close 7.34% 0.91% 0.12x Within
2021-11-04 After-Close 6.01% 1.37% 0.23x Within
2022-02-17 After-Close 5.20% 0.14% 0.03x Within
2022-04-21 After-Close 5.00% 13.25% 2.65x Exceeded
2022-11-08 After-Close 5.13% 4.20% 0.82x Within
2023-02-09 After-Close 4.76% 4.27% 0.90x Within
2023-05-04 After-Close 6.13% 3.29% 0.54x Within
2023-08-03 After-Close 6.52% 1.87% 0.29x Within
2023-11-07 After-Close 9.37% 0.69% 0.07x Within
2024-01-10 After-Close 3.77% 3.25% 0.86x Within
2024-05-07 After-Close 6.56% 20.19% 3.08x Exceeded
2024-08-06 After-Close 9.67% 2.14% 0.22x Within
2024-11-05 After-Close 12.37% 9.43% 0.76x Within
2025-01-08 After-Close 5.31% 0.60% 0.11x Within
2025-05-08 After-Close 8.87% 22.96% 2.59x Exceeded
2025-08-07 After-Close 10.17% 8.47% 0.83x Within
2025-11-06 After-Close 13.69% 35.94% 2.63x Exceeded
2026-01-07 After-Close 6.74% 4.51% 0.67x Within
2026-02-24 After-Close 11.43% 4.72% 0.41x Within
2026-05-07 After-Close 12.99% 8.37% 0.64x Within
2026-08-06 After-Close 11.78% 1.57% 0.13x Within
2026-11-05 After-Close 11.48% 12.76% 1.11x Exceeded

Earnings calendar: this week’s reports with expected vs actual moves →

GMED Options Activity & IV Rank

GMED IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 34.7%
7-DTE IV: 41.4%
Expected Move: $6.33
7-DTE Move: $4.88
Days to Exp: 39 (2026-12-18)

Options Flow · All expiries

Call Volume: 552
Put Volume: 377
P/C Volume: 0.683
BULLISH
Call OI: 3,341
Put OI: 4,315
P/C OI: 1.292
Total OI: 7,656

ATM Options Pricing

ATM Call: $3.50
ATM Put: $2.83
Call %: 4.6%
Put %: 3.7%

Chain Summary

Chain Volume: 929
Chain OI: 7,656
Last Updated: 11/9/2026
Spread Scanner
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Scanning bull put, bear call, iron condor and calendar spreads…

Dealer Positioning
LOW γ vs HISTORY

Estimated net dealer gamma is at the 5th percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
5%
vs own history
GEX tilt
-0.15
OI-weighted, today
Vanna tilt
+0.37
δ-sensitivity to IV
Charm tilt
-0.22
δ-decay vs time
Vanna tilt +0.37: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 24 ATM contracts, 4k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
No data
30 DTE / 10d —
— pts EXTREME
No data

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Loading the implied volatility surface…

Volatility Smile

Loading the implied volatility smile…

IV Rank (7 DTE)18.1LowNov 9
IV Rank (30 DTE)22.4LowNov 9
Straddle Price (30 DTE)$6.33Nov 9
Beta Analysis

Risk Metrics

Beta: 0.8855
Alpha: -13.72%
Correlation: 0.3196
R-Squared: 10.2%
Stock Volatility: 38.2%
Market Volatility: 13.8%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
Moderate volatility - stock generally follows market
Beta & Alpha Over Time
Notable investors who own GMED
4 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Bridgewater Associates Hedge fund
Ray Dalio
$27.8M
0.11%
#149 of 997+6.5%13F
Renaissance Technologies Hedge fund
Jim Simons
$15.6M
0.02%
#827 of 3138new13F
Millennium Management Hedge fund
Izzy Englander
$2.3M
0.00%
#2509 of 3716-98.2%13F
Rockefeller Capital Management Family office
Rockefeller family
$1.4M
0.00%
#1550 of 4729-4.3%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

GMED Institutional Ownership (13F)

Filings for 2026-06-30 · 295 already for 2026-09-30
Diluted shares outstanding: 137,006,250 (as of 2026-06-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

630 filers122,753,036 shares$9.63B value89.60% of float
# Filer Shares Value % of Total % of Float Period
1 BlackRock, Inc. Custodian 10,806,724 $853.84M 8.86% 7.89% 2026-06-30
2 Jupiter Topco LLC 8,200,423 $647.93M 6.73% 5.99% 2026-06-30
3 Vanguard Capital Management LLC 5,107,532 $403.55M 4.19% 3.73% 2026-06-30
4 Vanguard Portfolio Management LLC 4,994,385 $394.61M 4.10% 3.65% 2026-06-30
5 Invesco Ltd. Custodian 4,309,771 $340.52M 3.53% 3.15% 2026-06-30
6 KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC 4,279,730 $338.14M 3.51% 3.12% 2026-06-30
7 State Street Corp 3,714,029 $293.54M 3.05% 2.71% 2026-06-30
8 Sculptor Capital LP 3,000,000 $237.03M 2.46% 2.19% 2026-06-30
9 JPMorgan Chase & Co Custodian 2,743,850 $230.76M 2.40% 2.00% 2026-06-30
10 Dimensional Fund Advisors LP Custodian 3,007,442 $225.26M 2.34% 2.20% 2026-09-30
11 Swedbank AB 2,880,843 $215.78M 2.24% 2.10% 2026-09-30
12 AllianceBernstein L.P. 2,380,344 $205.09M 2.13% 1.74% 2026-06-30
13 Bank of Montreal Custodian 2,425,491 $191.64M 1.99% 1.77% 2026-06-30
14 Geode Capital Management, LLC Custodian 2,132,827 $159.79M 1.66% 1.56% 2026-09-30
15 Goldman Sachs Group Inc Custodian 1,781,608 $140.76M 1.46% 1.30% 2026-06-30
16 Arrowstreet Capital, Limited Partnership 1,716,621 $135.63M 1.41% 1.25% 2026-06-30
17 Allspring Global Investments Holdings, LLC 1,797,215 $133.73M 1.39% 1.31% 2026-09-30
18 Boston Trust Walden Corp 1,643,143 $123.07M 1.28% 1.20% 2026-09-30
19 Boston Partners 1,554,990 $122.85M 1.28% 1.14% 2026-06-30
20 GW&K Investment Management, LLC 1,453,206 $114.82M 1.19% 1.06% 2026-06-30
21 GENEVA CAPITAL MANAGEMENT LLC 1,417,067 $111.96M 1.16% 1.03% 2026-06-30
22 WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC 1,447,365 $108.41M 1.13% 1.06% 2026-09-30
23 Charles Schwab Investment Management, Inc. 1,246,322 $98.47M 1.02% 0.91% 2026-06-30
24 Quantinno Capital Management LP 1,219,098 $96.32M 1.00% 0.89% 2026-06-30
25 Norges Bank 1,127,051 $89.05M 0.92% 0.82% 2026-06-30
9 filers$36.06M notional
# Filer Notional Value % of Total Period
1 Sofinnova Investments, Inc. $15.80M 43.82% 2026-06-30
2 Jane Street Group, LLC Custodian $5.87M 16.28% 2026-06-30
3 Citadel Advisors LLC Custodian $4.45M 12.33% 2026-06-30
4 Twin Tree Management, LP $4.40M 12.20% 2026-06-30
5 IMC-Chicago, LLC Custodian $2.44M 6.77% 2026-09-30
6 Susquehanna International Group, LLP Custodian $1.62M 4.49% 2026-06-30
7 Walleye Capital LLC $529.37K 1.47% 2026-06-30
8 Simplex Trading, LLC Custodian $509.32K 1.41% 2026-09-30
9 Walleye Trading LLC $442.46K 1.23% 2026-06-30
7 filers$7.44M notional
# Filer Notional Value % of Total Period
1 Jane Street Group, LLC Custodian $2.23M 29.94% 2026-06-30
2 Twin Tree Management, LP $1.64M 21.98% 2026-06-30
3 Susquehanna International Group, LLP Custodian $1.20M 16.14% 2026-06-30
4 IMC-Chicago, LLC Custodian $1.02M 13.69% 2026-09-30
5 Citadel Advisors LLC Custodian $718.99K 9.66% 2026-06-30
6 Walleye Trading LLC $418.75K 5.63% 2026-06-30
7 Walleye Capital LLC $221.23K 2.97% 2026-06-30

GMED Insider Trading (Form 4)

Latest: 2026-11-05
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-11-05 Ann D Rhoads Director Sell (S) −5,000 $85.00 -$425.0K EDGAR
2026-09-16 James R Tobin Director Mixed
Exer +30,000 · Sell −30,000
 — $66.65 -$476.1K EDGAR
2026-08-19 Stephen T Zarrilli Director Mixed
Exer +25,000 · Sell −25,000
 — $70.15 -$844.2K EDGAR
2026-07-28 David D Davidar Director Gift (G) −2,500 — EDGAR
2026-06-09 David D Davidar Director Mixed
Sell −25,000 · Exer +25,000
 — $53.52 -$1.36M EDGAR
2026-06-08 Ann D Rhoads Director Exer (M) +25,000 $26.27 $656.8K EDGAR
2026-02-27 Kelly Huller EVP, GC, Corporate Secretary Mixed
Sell −20,000 · Exer +20,000
 — $69.04 -$1.02M EDGAR
2026-02-17 Kelly Huller EVP, GC, Corporate Secretary Mixed
Sell −10,000 · Exer +10,000
 — $66.66 -$420.3K EDGAR
2026-01-23 Kelly Huller EVP, GC, Corporate Secretary Grant (A) +40,000 opt — EDGAR
2026-01-23 David D Davidar Director Grant (A) +15,000 opt — EDGAR
2026-01-23 Dan Wolterman Director Grant (A) +15,000 opt — EDGAR
2026-01-23 John A DeFord Director Grant (A) +15,000 opt — EDGAR
2026-01-23 Stephen T Zarrilli Director Grant (A) +15,000 opt — EDGAR
2026-01-23 James R Tobin Director Grant (A) +15,000 opt — EDGAR
2026-01-23 Ann D Rhoads Director Grant (A) +15,000 opt — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

GMED Insider Holdings

11 insiders · @ $76.12
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 David D Davidar Director 673,642 $51.28M -$42.54M 47 2026-07-28
2 Daniel T Scavilla President, CEO 130,000 $9.90M -$34.20M 17 2025-03-28
3 David C Paul Executive Chairman 60,417 $4.60M -$234.68M 25 2026-01-23
4 Ann D Rhoads Director 35,384 $2.69M -$3.47M 23 2026-11-05
5 Dan Wolterman Director 24,025 $1.83M $0 4 2026-01-23
6 Kelly Huller EVP, GC, Corporate Secretary 20,000 $1.52M -$8.05M 25 2026-02-27
7 John A DeFord Director 15,578 $1.19M $0 5 2026-01-23
8 Keith W Pfeil President, CEO 14,167 $1.08M -$6.28M 19 2026-01-23
9 Leslie V Norwalk Director 10,419 $793.1K -$1.18M 8 2026-01-23
10 Kyle Kline Senior Vice President, CFO 3,594 $273.6K -$2.03M 5 2026-01-23
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

GMED Board & Officers

As of SEC filings through Nov 5, 2026

Directors 10

Officers 4

  • Keith W Pfeil · President, CEO · listed since Aug 2025
  • Kyle Kline · Senior Vice President, CFO · since Jul 18, 2025
  • Kelly Huller · EVP, GC, Corporate Secretary · listed since Jan 2026
  • David C Paul · Executive Chairman · listed since Jan 2018

10% owners 1

Changes in the last 10 years (25)
Mar 23, 2026The company announced the departure of John A DeFord from the board in an SEC filing
Jan 23, 2026Kelly Huller listed as EVP, GC, Corporate Secretary (previously SVP, GC, Corporate Secretary) in SEC filings
Aug 27, 2025Keith W Pfeil listed as President, CEO (previously COO, CFO) in SEC filings
Aug 27, 2025Keith W Pfeil first listed as a director in an SEC filing
Jul 18, 2025The company announced the departure of Daniel T Scavilla from the board in an SEC filing
Jul 18, 2025Kyle Kline became Senior Vice President, CFO
Jan 14, 2025Keith W Pfeil listed as COO, CFO (previously SVP, Chief Financial Officer) in SEC filings
Sep 1, 2023Leslie V Norwalk became a director
Sep 1, 2023John A DeFord became a director
Sep 1, 2023Dan Wolterman became a director
Apr 22, 2022Daniel T Scavilla listed as President, CEO (previously EVP, Chief Commercial Officer) in SEC filings
Apr 22, 2022Daniel T Scavilla first listed as a director in an SEC filing
Apr 20, 2022The company announced the departure of David M Demski from the board in an SEC filing
Jan 24, 2020Kelly Huller listed as SVP, GC, Corporate Secretary (previously SVP, General Counsel) in SEC filings
Jan 24, 2020David M Demski listed as President, CEO (previously Chief Executive Officer) in SEC filings
Jan 24, 2020Daniel T Scavilla listed as EVP, Chief Commercial Officer (previously Senior VP and CFO) in SEC filings
Dec 11, 2019Robert Andrew Douglas became a director
Aug 19, 2019Keith W Pfeil became SVP, Chief Financial Officer
May 1, 2019Stephen T Zarrilli became a director
Feb 27, 2019Kelly Huller became SVP, General Counsel
Not reported recently (8)
  • Daniel T Scavilla · Last reported as President, CEO in an SEC filing dated Mar 28, 2025
  • David M Demski · Last reported as President, CEO in an SEC filing dated Jan 31, 2022
  • Anthony L Williams · Last reported as President in an SEC filing dated Mar 7, 2019
  • Kurt Wheeler · Last reported as a director in an SEC filing dated Feb 11, 2019
  • Robert Liptak · Last reported as a director in an SEC filing dated Feb 11, 2019
  • Steven Payne · Last reported as Chief Accounting Officer in an SEC filing dated Feb 11, 2019
  • Eric Schwartz · Last reported as Senior VP and General Counsel in an SEC filing dated Jun 27, 2018
  • A Brett Murphy · Last reported as President, Commerical Op in an SEC filing dated Feb 6, 2018
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

GMED Proposed Insider Sales (Form 144)

Latest: 2026-11-04
Last 30d: 1 filing · $425K notice value  ·  Last 90d: 3 filings · $4.8M notice value · 3 unique filers · 33% under 10b5-1 plans

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Top 90-day filers: TOBIN JAMES R (1, $2.2M) · ZARRILLI STEPHEN T (1, $2.2M) · RHOADS ANN D (1, $425K)
Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-11-04 RHOADS ANN D Director 5,000 $425.0K 2026-11-04 Raymond James & Associates, Inc. 10b5-1 EDGAR
2026-09-15 TOBIN JAMES R Director 30,000 $2.24M 2026-09-15 Raymond James & Associates Inc. — EDGAR
2026-08-18 ZARRILLI STEPHEN T Director 25,000 $2.18M 2026-08-18 Raymond James & Associates, Inc. — EDGAR
2026-06-05 Davidar David D Director 25,000 $2.02M 2026-06-05 Raymond James & Associates — EDGAR
2026-04-14 DeFord John A Former Director 30,000 $2.79M 2026-04-14 Raymond James & Associates — EDGAR
2026-02-25 Huller Kelly Officer 20,000 $1.89M 2026-02-25 Raymond James & Associates 10b5-1 EDGAR
2026-02-12 Huller Kelly Officer 10,000 $876.0K 2026-02-12 Raymond James & Associates 10b5-1 EDGAR
2026-01-08 Kline Kyle Officer 3,594 $363.2K 2026-01-08 RAYMOND JAMES & ASSOCIATES 10b5-1 EDGAR
2026-01-08 Norwalk Leslie V Director 2,000 $202.0K 2026-01-08 Raymond James & Associates 10b5-1 EDGAR
2025-12-12 Norwalk Leslie V Director 4,000 $355.0K 2025-12-12 Raymond James & Associates 10b5-1 EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-05
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Filing Date Event Link
2026-11-05 Earnings results · Other events EDGAR
2026-08-06 Earnings results EDGAR
2026-06-04 Director or officer change · Shareholder vote results EDGAR
2026-05-07 Earnings results EDGAR
2026-03-23 Director or officer change · Regulation FD disclosure EDGAR
2026-02-24 Earnings results EDGAR
2026-01-07 Earnings results EDGAR
2025-11-06 Earnings results EDGAR
2025-08-07 Earnings results EDGAR
2025-07-21 Earnings results · Director or officer change · Regulation FD disclosure EDGAR
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Filing Date Accession Link
2026-02-24 0001628280-26-011209 EDGAR
2025-02-20 0001562762-25-000026 EDGAR
2024-02-21 0001562762-24-000032 EDGAR
2023-02-21 0001562762-23-000048 EDGAR
2022-02-17 0001562762-22-000037 EDGAR
2021-02-17 0001562762-21-000036 EDGAR
2020-02-20 0001237831-20-000010 EDGAR
2019-02-21 0001237831-19-000014 EDGAR
2018-02-22 0001237831-18-000012 EDGAR
2017-03-16 0001237831-17-000009 EDGAR
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
Filing Date Accession Link
2026-11-05 0001628280-26-071165 EDGAR
2026-08-06 0001628280-26-054450 EDGAR
2026-05-07 0001628280-26-032290 EDGAR
2025-11-06 0001237831-25-000031 EDGAR
2025-08-07 0001562762-25-000200 EDGAR
2025-05-08 0001562762-25-000118 EDGAR
2024-11-05 0001562762-24-000254 EDGAR
2024-08-06 0001562762-24-000199 EDGAR
2024-05-07 0001562762-24-000126 EDGAR
2023-11-07 0001562762-23-000407 EDGAR
ETF Holders
146 ETFs hold GMED
25 shown · $1.62B total exposure · 0.18% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 IJH iShares Core S&P Mid-Cap ETF iShares (BlackRock) 0.24% $287.5M $121.4B 2026-11-06
2 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.01% $269.9M — 2026-09-30
3 VB Vanguard Morningstar Small-Cap ETF Vanguard 0.11% $189.8M — 2026-09-30
4 VBK Vanguard Morningstar Small-Cap Growth ETF Vanguard 0.24% $105.7M — 2026-09-30
5 DFAT Dimensional US Targeted Value ETF Dimensional 0.31% $95.5M — 2026-11-05
6 VXF Vanguard Extended Market ETF Vanguard 0.10% $94.3M — 2026-09-30
7 MDY State Street® SPDR® S&P MIDCAP 400® ETF Trust SPDR (State Street) 0.27% $69.5M $25.6B 2026-11-05
8 DFAS Dimensional US Small Cap ETF Dimensional 0.15% $51.1M — 2026-11-05
9 SPMD State Street® SPDR® Portfolio S&P 400™ Mid Cap ETF SPDR (State Street) 0.27% $50.0M $18.3B 2026-11-05
10 IJK iShares S&P Mid-Cap 400 Growth ETF iShares (BlackRock) 0.48% $48.5M $10.2B 2026-11-06
11 SCHA Schwab U.S. Small-Cap ETF Nport 0.19% $43.9M — 2026-08-31
12 IHI iShares U.S. Medical Devices ETF iShares (BlackRock) 0.99% $39.7M $4.0B 2026-11-06
13 IWR iShares Russell Mid-Cap ETF iShares (BlackRock) 0.06% $34.0M $56.9B 2026-11-06
14 XOVR ERShares Private-Public Crossover ETF Nport 1.35% $29.4M — 2026-06-30
15 ROBO ROBO Global Robotics and Automation Index ETF Nport 1.35% $26.8M — 2026-07-31
16 DFAC Dimensional US Core Equity 2 ETF Dimensional 0.03% $26.0M — 2026-11-05
17 VHT Vanguard Health Care ETF Vanguard 0.12% $25.9M — 2026-09-30
18 SCHM Schwab U.S. Mid-Cap ETF Nport 0.17% $25.5M — 2026-08-31
19 FXH First Trust Health Care AlphaDEX® Fund First Trust 2.16% $25.2M $1.2B 2026-11-06
20 IWD iShares Russell 1000 Value ETF iShares (BlackRock) 0.02% $17.5M $82.9B 2026-11-06
21 MDYG State Street® SPDR® S&P 400™ Mid Cap Growth ETF SPDR (State Street) 0.55% $15.0M $2.7B 2026-11-05
22 IVOO Vanguard S&P Mid-Cap 400 ETF Vanguard 0.25% $14.0M — 2026-09-30
23 GRPM Invesco S&P MidCap 400 GARP ETF Invesco 1.88% $11.6M — 2026-11-05
24 FNDA Schwab Fundamental U.S. Small Company ETF Nport 0.13% $11.6M — 2026-08-31
25 IWS iShares Russell Mid-Cap Value ETF iShares (BlackRock) 0.08% $11.4M $14.8B 2026-11-06
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
19.50
TTM Diluted EPS
$3.90
TTM Revenue
$3.14B
TTM Net Income
$535.43M
TTM Op. Cash Flow
$910.39M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q2 '262026-06-30$789.61M$151.57M$1.10$209.74M
Q1 '262026-03-31$759.85M$124.30M$0.90$202.36M
Q4 '252025-12-31$826.42M$140.59M$1.02$248.59M
Q3 '252025-09-30$769.05M$118.97M$0.88$249.69M
Q2 '252025-06-30$745.34M$202.85M$1.49$77.86M
Q1 '252025-03-31$598.12M$75.46M$0.54$177.30M
Q4 '242024-12-31$657.29M$26.50M$0.19$210.34M
Q3 '242024-09-30$625.71M$51.84M$0.38$203.65M
Q2 '242024-06-30$629.69M$31.76M$0.23$54.09M
Q1 '242024-03-31$606.67M$-7.12M$-0.05$52.55M
Q4 '232023-12-31$616.53M$15.03M$0.09$91.67M
Q3 '232023-09-30$383.64M$998.00K$0.01$46.05M
Q2 2026 • period ending 2026-06-30 • filed 2026-08-06
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
19.50
P/B
2.18
P/S
3.31
EV/EBITDA
10.40
EV/Sales
3.15
ROE
11.2%
ROA
9.8%
Div Yield
0.00%
FCF Yield
8.74%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$10.42B
as of 2026-11-09

GMED vs Peers

Related companies, largest first
Company Market cap P/E Revenue growth YTD IV rank
ABT Abbott Laboratories $190.4B 40.9 +10.0% −11.1% 20
ISRG Intuitive Surgical Inc. $160.0B 55.8 +20.5% −17.9% 18
MDT Medtronic plc $130.2B 25.4 +9.8% +7.6% 59
NTRA Natera, Inc. Common Stock $45.1B — +36.6% +40.0% 43
RMD ResMed Inc. $33.1B 21.5 +9.0% −3.4% 22
DXCM DexCom, Inc. $29.6B 32.0 +13.0% +22.1% 40
GH Guardant Health, Inc. Common Stock $20.4B — +42.7% +58.3% 25
ALGN Align Technology Inc $11.7B 30.7 +4.4% +12.9% 14
GMED GLOBUS MEDICAL INC $9.4B 19.5 +19.7% −12.8% 22
Peer median $39.1B 31.4 +11.5% +10.2% 23

P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.

Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
8.19M
SI % of Float
6.25%
Days to Cover
5.47
Short Vol Ratio
36.8%
Free Float
131.09M
Float %
97.6%
Short interest 2026-10-15 • Short volume 2026-11-06 • Float 2026-08-14